A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors (NCT05494762)
BGB-A317-B167-101
This trial is No longer recruiting
Registration number NCT05494762
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Malaka Ameratunga
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR